Correlation of pain with substance P and neurokinin-1 receptor in the L5−S2 spinal cord in rats with chronic nonbacterial prostatitis

The incidence of prostate pain is 90%–95% in prostatitis. The symptoms are persistent, which is prone to relapse and difficult to be cured. It seriously affects the survival and quality of life of patients. This study analyzed the correlation between pain and substance P (SP) and neurokinin-1 receptors (NK-1R) in the L5–S2 spinal cord of chronic nonbacterial prostatitis (CNP) rats, which may give a new way to explore the pathogenesis and treatment of pain in prostatitis. We randomly divided the rats into control group, 45 d group, 60 d group, and 90 d group. After making a rat model with autoimmune method, the paw withdrawal threshold (PWT) was measured, the histomorphological changes in the prostate was observed by transmission electron microscopy and light microscopy. The expression of SP and NK-1R was measured by immunohistochemistry, and the concentrations of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-2 (IL-2), and interleukin-10 (IL-10) were measured by enzyme linked immunosorbent assay (ELISA). Compared with the control group, the PWT was decreased by 34.21%, 41.90% and 64.79%, TNF-α was increased by 74.19%, 89.45% and 132.15%, IL-1β was increased by 148.88%, 181.95% and 250.74%, IL-2 was increased by 75.97%, 82.15% and 128.57% and IL-10 was increased by 31.04%, 63.28% and 212.99% in the 45 d group, 60 d group and 90 d group respectively. Microscope observation showed the structure of prostate tissue in control group was normal. However, the prostate tissue had obvious inflammatory response with the model extension. The expressions of SP and NK-1R in each model group were significantly higher than the control group. There was a significant correlation between pain and SP in L5–S2 spinal cord in CNP rats. These findings are indicative of a correlation between pain and the expression levels of SP and NK-1R in the L5–S2 spinal cord of CNP rats.

Chronic nonbacterial prostatitis; Pain; Substance P; Neurokinin-1 receptor; Rat model

[1] Shang Y, Liu C, Cui D, Han G, Yi S. The effect of chronic bacterial prostatitis on semen quality in adult men: a meta-analysis of case-control studies. Scientific Reports. 2014; 4: 7233.

[2] Kulchavenya EVK, Shvetsova OPS, Breusov AAB. Rationale of use and effectiveness of Longidaza in patients with chronic prostatitis. Urologiia. 2018; 64–71. (In Russian)

[3] Han P, Lai YJ, Chen J, Zhang XN, Chen JL, Yang X. Protective potential of the methanol extract of Macrothelypteris oligophlebia rhizomes for chronic non-bacterial prostatitis in rats. Pakistan Journal of Pharmaceutical Sciences. 2016; 29: 1217–1222.

[4] Chen YZ, Gong XY, Zheng W, Xue CH, Li YQ. Interventional mechanism of Qianlie Huazhuo pill in rats with chronic nonbacterial prostatitis. Journal of Anhui University of Chinese Medicine. 2018; 37: 4. (In Chinese)

[5] Hajighorbani M, Ahmadi-hamedani M, Shahab E, Hayati F, Kafshdoozan K, Keramati K, et al. Evaluation of the protective effect of pentoxifylline on carrageenan-induced chronic non-bacterial prostatitis in rats. Inflam-mopharmacology. 2017; 25: 343–350.

[6] Huang M, Huang Q, Wu J, Qin T, Meng D, Urology DO. Correlation between the regulation of TGF-β1 signaling pathway by miR-150 and chronic nonbacterial prostatitis. Journal of Youjiang Medical University for Nationalities. 2019; 41: 489–499, 504.

[7] Middeldorp J, Hol EM. GFAP in health and disease. Progress in Neurobiology. 2011; 93: 421–443.

[8] Lagerström MC, Rogoz K, Abrahamsen B, Lind A, Ölund C, Smith C, et al. A sensory subpopulation depends on vesicular glutamate transporter 2 for mechanical pain, and together with substance P, inflammatory pain. Proceedings of the National Academy of Sciences. 2011; 108: 5789–5794.

[9] Zhang YQ, Wang Y, Li M, Lu XJ, Gao YS, Liu B, et al. Establishment of a rat model of autoimmune prostatitis induced by prostate tissue antigen protein. Chinese Journal of Integrated Traditional and Western Medicine Surgery. 2008; 14: 584–587.

[10] Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. Journal of Neuroscience Methods. 1994; 53: 55–63.

[11] Gao W, Li Q, Liu YQ, Li HS, Shi CX. Clinical study on treating chronic pelvic pain syndrome with moxibustion. Primary Medical Forum. 2020; 24: 3.

[12] Xu X, Hou J, Lv J, Huang Y, Pu J, Wang L. Overexpression of lncRNA GAS5 suppresses prostatic epithelial cell proliferation by regulating COX-2 in chronic non-bacterial prostatitis. Cell Cycle. 2019; 18: 923–931.

[13] Magri V, Marras E, Restelli A, Wagenlehner FME, Perletti G. Multimodal therapy for category III chronic prostatitis/chronic pelvic pain syndrome in UPOINTS phenotyped patients. Experimental and Therapeutic Medicine. 2015; 9: 658–666.

[14] Magistro G, Wagenlehner FME, Grabe M, Weidner W, Stief CG, Nickel JC. Contemporary management of chronic prostatitis/chronic pelvic pain syndrome. European Urology. 2016; 69: 286–297.

[15] Guu S, Geng J, Chao I, Lin H, Lee Y, Juan Y, et al. Efficacy of low-intensity extracorporeal shock wave therapy on men with chronic pelvic pain syndrome refractory to 3-as therapy. American Journal of Men’s Health. 2018; 12: 441–452.

[16] Wang HZ, Li M. Treating 50 cases of chronic prostatitis with Qingreishitongyu decoction. Chinese Medicine Science and Technology. 2019; 26: 2. (In Chinese)

[17] Nickel JC, Nyberg LM, Hennenfent M. Research guidelines for chronic prostatitis: consensus report from the first national institutes of health international prostatitis collaborative network. Urology. 1999; 54: 229–233.

[18] Krieger J, Ross S, Riley D. Chronic prostatitis: epidemiology and role of infection. Urology. 2002; 60: 8–12.

[19] Fogg RN, Mydlo JH. Nonbacterial infections of the genitourinary tract. Practical Urology: Essential Principles and Practice. 2011; 30: 323–337.

[20] Schaeffer AJ. Etiology and management of chronic pelvic pain syndrome in men. Urology. 2004; 63: 75-84.

[21] Chen Y, Song B, Jin X, Xiong E, Zhang J. Possible mechanism of referred pain in the perineum and pelvis associated with the prostate in rats. Journal of Urology. 2005; 174: 2405–2408.

[22] Zhang JH, Han LW, Qu JB, Zhou HC, Jia YR, Liu JF. Effect of pregabalin on expression of GFAP and SP in spinal cord of CCI model rats. Chinese Journal of Pain Medicine. 2018; 24: 6.

[23] Peng XU, Sikandaer, Wang Y, Center U. Correlation analysis of the expression of SP and β-endorphin with chronic pelvic pain syndrome. Chinese Journal of Human Sexuality. 2018; 27: 91–94. (In Chinese)

[24] Howard F. Chronic pelvic pain. Obstetrics & Gynecology. 2003; 101: 594–611.

[25] Muñoz M, Coveñas R. Involvement of substance P and the NK-1 receptor in human pathology. Amino Acids. 2014; 46: 1727–1750.

[26] Takasusuki T, Yaksh TL. Regulation of spinal substance P release by intrathecal calcium channel blockade. Anesthesiology. 2011; 115: 153–164.

[27] Wen ZP, Hong ZM, Lin XY, Lin F, Quan L, Wang Y, et al. Effect of Qianlie Huoxue decoction on inflammatory factors in the prostate of rats with autoimmune prostatitis. World Journal of Integrated Chinese and Western Medicine. 2010; 5: 396–400. (In Chinese)

[28] Liu Y, Song G, Zhang C. Prostatic inflammation-induced chronic pelvic pain: roles of substance P and c-fos in the spinal cord. National Journal of Andrology. 2015; 21: 681–686.

[29] Du H, Zhao WM. The pathogenesis of pain in chronic prostatitis. Journal of Modern Urology. 2017; 22: 76–78.

[30] Middeldorp J, Hol EM. GFAP in health and desease. Progress in Neurobiology. 2011; 93: 421–443.